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neuropathic pain through its acetyltransferase
activity in rats following chronic constriction
injury (CCI)
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Background: Neuropathic pain is detrimental to human health; however, its pathogenesis still remains largely
unknown. Overexpression of pain-associated genes and increased nociceptive somato-sensitivity are well observed
in neuropathic pain. The importance of epigenetic mechanisms in regulating the expression of pro- or
anti-nociceptive genes has been revealed by studies recently, and we hypothesize that the transcriptional
coactivator and the histone acetyltransferase E1A binding protein p300 (p300), as a part of the epigenetic
mechanisms of gene regulation, may be involved in the pathogenesis of neuropathic pain induced by chronic
constriction injury (CCI). To test this hypothesis, two different approaches were used in this study: (I)
down-regulating p300 with specific small hairpin RNA (shRNA) and (II) chemical inhibition of p300 acetyltransferase
activity by a small molecule inhibitor, C646.
Results: Using the CCI rat model, we found that the p300 expression was increased in the lumbar spinal cord on
day 14 after CCI. The treatment with intrathecal p300 shRNA reversed CCI-induced mechanical allodynia and
thermal hyperalgesia, and suppressed the expression of cyclooxygenase-2 (COX-2), a neuropathic pain-associated
factor. Furthermore, C646, an inhibitor of p300 acetyltransferase, also attenuated mechanical allodynia and thermal
hyperalgesia, accompanied by a suppressed COX-2 expression, in the spinal cord.
Conclusions: The results suggest that, through its acetyltransferase activity in the spinal cord after CCI, p300
epigenetically plays an important role in neuropathic pain. Inhibiting p300, using interfering RNA or C646, may be a
promising approach to the development of new neuropathic pain therapies.
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Neuropathic pain is a direct consequence of a lesion
or disease affecting the somatosensory system at the
peripheral or central level [1,2] which is characterized
by spontaneous pain, hyperalgesia, allodynia, and
paresthesia. The underlying mechanisms of neuropathic
pain are still poorly understood, and, thus, its treatment
remains a challenge. Accumulative evidence indicates
that the expression of pain-associated genes in sensory* Correspondence: qulianguo5866@gmail.com
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reproduction in any medium, provided the orneurons greatly contributes to the development and
maintenance of neuropathic pain [3,4].
In the rat spinal cord, COX-2 is expressed constitu-
tively in locations consistent with the neuroanatomical
substrates of spinal nociception [5]. It is an inducible en-
zyme that increases significantly following an injury, last-
ing for several months or even several years [6,7].
Overexpression of COX-2 in injured nerve is observed
in rats following CCI, partial sciatic nerve ligation, spinal
nerve ligation, and complete sciatic nerve transaction
in studies [7,8]. COX-2 produces prostaglandins that
contribute to the development and maintenance of
spinal hyperexcitability after peripheral nerve injury. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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after CCI injury can attenuate the development of
hyperalgesia and/or allodynia in chronic neuropathic
pain in rats [11-14], and can also inhibit the CCI-
induced elevation of neuronal COX-2 expression in
the spinal cord [8]. All these findings demonstrate that
COX-2 pathogenetically contributes to hyperalgesia
and allodynia at the spinal cord level, and that the al-
teration of COX-2 expression is an important feature
in neuropathic pain.
Epigenetics is an emerging field in biology, which
reveals that stable changes in gene expression can
occur without alteration in the DNA sequence, as
other (epigenetic) factors are also involved in gene ex-
pression rather than genes alone. Covalent modifica-
tion of the DNA-packaging histone that regulates the
expression of pro- or antinociceptive genes is one of
the characterized mechanisms of epigenetics [15-17].
As a histone acetyltransferase, p300 is a major con-
tributor to the regulation of gene expression [18]. It is
expressed ubiquitously and plays an important role in
a wide range of biological processes. p300 regulates
the expression of various kinds of genes through
bridging, scaffolding or histone acetyltransferase (HAT)
activity, epigenetically contributing to illnesses such as
inflammation, tumor, neurodegenerative diseases and
so on [19-21]. However, little is known about the ex-
pression of p300 and its role in the CCI-induced
neuropathic pain. There are studies demonstrating
p300’s essential role in COX-2 transcriptional activa-
tion in the cell signaling pathway using chromatin
immunoprecipitation (ChIP) analysis [22,23].
Taking these facts together, we hypothesized that
p300 may be epigenetically involved in neuropathic pain
through regulating the expression of neuropathic pain-
associated factor COX-2 in CCI rats. In this study, we
examined p300 and COX-2 expression in the spinal
cord in the neuropathic pain rats after CCI. We evalu-
ated the effects of intrathecal administration of lentiviral
vectors encoding small interfering RNA specifically
against the p300 gene (LV-shp300) on COX-2Figure 1 The detection of lentiviral neurocyte transfection. Fluorescen
lentiviral vectors into the neurons of spinal dorsal horn. GFP was detected inexpression and neuropathic pain in the CCI rats. We
also used C646 to inhibit p300 acetyltransferase activity
[24] to further verify p300’s role in neuropathic pain.
Results
Verification of the transfected LV-shp300 in the cells of
spinal dorsal horn
The lentiviral vectors that were carrying a plasmid
expressing green fluorescent protein (GFP) were deliv-
ered into the subarachnoid space to transfect the cells of
the spinal cord (Figure 1). The fresh sections taken from
the spinal cord tissue on day 14 after CCI were observed
under fluorescence microscopy. The GFP-positive cells
were clearly seen in neurons in the group of lentiviral
vectors encoding small interfering RNA as the negative
control of p300 gene (LV-NC) and LV-shp300-treated
rats.
Changes in behavior and neuropathic pain measurements
After CCI, the rats gradually showed the typical signs of
hyperalgesia and allodynia such as toe closing, foot ever-
sion, and paw-licking. Behaviors in sham-operated rats
were not obviously changed. The changes in ipsilateral
mechanical withdrawal threshold (MWT) and thermal
withdrawal latency (TWL) were demonstrated in
Figure 2. There was no significant difference in MWT and
TWL among the groups (P > 0.05) after catheterization
and before CCI surgery. MWT and TWL of CCI rats
decreased on day 3 after CCI and were further reduced
on day 5 compared with sham-operated rats (sham, P <
0.05), which indicated that the mechanical allodynia and
thermal hyperalgesia had been developed in CCI rats.
Later, in normal saline (NS)-treated group, LV-NC-
treated group and C37 (inactive analog of C646)-treated
group, MWT and TWL went much lower on day 7, and
this persisted at the end of the study (P < 0.05). In con-
trast, MWT and TWL were constantly recovering from
day 10 to the end of the study in LV-shp300 and C646-
treated rats (P < 0.05). The inhibition of p300 with spe-
cific shRNA or C646 attenuated the pain during the
steady-state of neuropathic pain in our study, suggestingce microscopy images of GFP expression showing transfection of
NC-treated rats (A) and LV-shp300-treated rats (B). Scale bars = 100um.
Figure 2 Changes of MWT and TWL data (mean ± SEM) in all rats. A: Changes on thermal hyperalgesia in all rats. B: Changes on mechanical
allodynia in all rats. Comparison of TWL and MWT in rats with different treatments: *P < 0.05 vs. sham-operated group; #P < 0.05 vs. NS and
NC-treated groups. ΔP < 0.05 vs. C37-treated group.
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and neuropathic pain during CCI.
Changes in p300 expression
To evaluate the inhibitory effect of LV-shp300 on p300
mRNA expression in the spinal cord, reverse transcription-
polymerase chain reaction (RT-PCR) was performed at the
end of the study. As shown in Figure 3A, B, while sham-Figure 3 The effects of LV-shp300 and C646 on p300 expression in th
the lumbar spinal cord in all rats. The β-actin fragment was used as an inte
P300/β-actin in rats on mRNA level, n = 5. C: Expression of protein p300 in
P300/PCNA in all rats on protein level, n = 5. S: sham-operated rats; NS: NS-
CCI rats. C37: C37-treated CCI rats; C646:C646-treated CCI rats. *P < 0.05 vs.operated rats showed the lowest p300 mRNA expression
level, NS and NC-treated rats had the highest p300 mRNA
expression (P < 0.05 vs. sham control). The p300 expression
was significantly decreased in LV-shp300-treated rats com-
pared with those in NS and NC treated rats (P < 0.05), indi-
cating that the intrathecal LV-shp300, reversed the
upregulated p300 expression after CCI. Noteworthily, C646,
the high specificity inhibitor of p300 acetyltransferase activity,e lumbar spinal cord in rats. A: Expression of mRNAs for p300 in
rnal control. B: The mean (±SEM) of integral optical density (IOD) of
the lumbar spinal cord in all rats. D: The mean (±SEM) of IOD of
treated CCI rats; NC: LV-NC-treated CCI rats; shp300: LV-shp300-treated
sham-operated group; #P < 0.05 vs. NS and NC-treated groups.
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which was similar to its inactive analog, C37 (P > 0.05).
Similarly, Western blot analysis showed that the p300
protein levels paralleled the mRNA levels (Figure 3C, D).
These findings also indicated that the inhibitory effects
of a single injection of lentivirus carrying p300 shRNA
were persistent for at least 7 days on the spinal cord level,
which is consistent with Song’s report [25]. And C646
had no role in p300 protein expression quantitatively.
The findings in immunostaining of p300 were also con-
sistent with RT- PCR and Western blot results. As shown
in Figure 4, p300 immunoreactivity was seen mainly in the
nucleus in the superficial laminas of spinal dorsal horn in
rats. Increased immunoreactivity throughout the ipsilat-
eral dorsal horn in vehicle (NS, NC and C37)-treated CCI
rats were evidenced in Figure 4B, C and E, compared with
that in sham-operated group (Figure 4A). The increased
p300 immunoreactivity was particularly concentrated at
layers I-III, which is one of the major areas for nociceptive
signal processing. p300 immunoreactivity was moderately
decreased in LV-shp300-treated CCI rats (Figure 4D).
Images of the C646-treated group were similar to those in
vehicle-treated CCI group (Figure 4F). The overexpression
of p300 in the lumbar spinal cord is similar to Matsumo-
to’s report [26].
LV-shp300 and C646 injection attenuated CCI-induced
p300 protein recruitment to COX-2 promoter region
The effect of CCI on p300 (protein) binding to COX-2
promoter was evaluated by ChIP assay. p300 wasFigure 4 Representative images of p300 immunoreactivity in rats’ spi
was mainly located in the nucleus but not in the cytoplasm. Representative
p300 expression in sham-operated rats (A), CCI-induced overexpression of
C646-treated rats (F), p300 shRNA moderately decreased the p300 expressiimmunoprecipitated with specific antibodies, and the
COX-2 promoter region containing the essential binding
sites for promoter activation was detected by real time
PCR. In order to quantify the relative amount of p300
associated with COX-2 promoter, total input DNA and
the immunoprecipitated DNA were used as templates
for PCR with primers for the rat COX-2 gene promoter.
As shown in Figure 5, p300 binding to chromatin COX-
2 promoter region was increased significantly in the
groups of NS, NC, and C37-treated rats compared with
the group of sham-operated rats(P < 0.05). However, it
was decreased significantly in the groups treated with
p300 shRNA and C646 (P < 0.05). The decreases were
about 56.21% in p300 shRNA group (versus NC group)
and 52.24% in C646 group (versus C37 group) of that
induced by CCI. These results demonstrated that both
the LV-shp300 and the C646 attenuated this CCI-
induced p300 binding to the COX-2 promoter region.
LV-shp300 and C646 injection decreased CCI-induced
COX-2 expression
RT-PCR analysis demonstrated clear expression of COX-
2 and β-actin mRNA in the lumbar spinal cord among
the groups. As shown in Figure 6A, B, sham-operated
rats showed basic COX-2 mRNA expression level,
and significant increases were seen in NS, NC and
C37-treated CCI rats (P < 0.05 vs. sham control). COX-2
expression was significantly decreased in shp300 and
C646 treated rats compared with the vehicle treated CCI
rats (P < 0.05).nal dorsal horn among different groups. p300 immunoreactivity
p300-positive cells were pointed by arrows (Scale bars = 50um); basal
p300 in NS-treated rats (B), NC-treated rats (C), C37-treated rats (E) and
on in LV-shp300-treated CCI rats (D).
Figure 5 ChIP assays in shRNA treated and p300
acetyltransferase inhibitor treated rats. Reactions were performed
with normal mouse IgG or anti-p300 antibodies. Real time PCR was
used to quantify the enrichment of p300 promoter region of the
cox-2 gene. Comparison between rats with different treatments:
*P < 0.05 vs. sham-operated group; #P < 0.05 vs. NS and NC-treated
groups. ΔP < 0.05 vs. C37-treated group. S: sham-operated rats;
NS: NS-treated CCI rats; NC: LV-NC-treated CCI rats; shp300:
LV-shp300-treated CCI rats. C37: C37-treated CCI rats;
C646:C646-treated CCI rats.
Zhu et al. Molecular Pain 2012, 8:84 Page 5 of 11
http://www.molecularpain.com/content/8/1/84Western blot analysis revealed that the COX-2 expres-
sion on protein level was consistent with those from RT-
PCR. As shown in Figure 6C, D, the proteins of COX-2
in the lumbar spinal cord in all rats 14 days following
CCI were expressed clearly. There were significant dif-
ferences among the groups: COX-2 expression wasFigure 6 The effects of intrathecal injections of p300 shRNA and p300
COX-2 mRNA in the lumbar spinal cord in all rats. Typical results are shown
level, n = 5; C: Expression of protein COX-2 in the lumbar spinal cord in all
COX-2/β-actin in all rats on protein level, n = 5. S: sham-operated rats; NS: N
LV-shp300-treated CCI rats. C37: C37-treated CCI rats; C646: C646-treated CC
NC-treated groups. ΔP < 0.05 vs. C37-treated group.increased significantly in NS-treated and NC-treated rats
(P < 0.05, vs. sham control), whereas it was significantly
decreased in LV-shp300-treated rats (P < 0.05). COX-2
expression in C646-treated rats also decreased (P < 0.05,
vs. C37-treated group), suggesting that p300 regulates
COX-2 expression probably through its acetyltransferase
activity, C646 directly inhibits the acetyltransferase
activity of p300, and thus, suppresses COX-2 expression.
The double immunofluorescence staining of p300 and
COX-2 indicated that p300 co-localized with COX-2
in the spinal dorsal horn neurons (Figure 7), serving
as evidence supporting an interaction between p300
and COX-2.
Discussion
Intrathecal application of shRNA has become a suitable
approach for studies on small molecules such as drugs,
receptors, or other proteins [25,27,28]. Small interfer-
ence RNA (siRNA)-induced knockdown can be gener-
ated by the expression of the vector-mediated siRNA in
the genome [29]. In this study, we adopted the system of
lentiviral vector-mediated hairpin RNAs as it has a more
efficient transfection rate in tissues in vivo compared
with the system based on polyethylenimine/DNA com-
plexes. Our results showed that LV-shp300 was success-
ful transfected into the cells in the spinal cord
(Figure 1), and it significantly silenced the p300 gene in
LV-shp300-treated rats (Figure 3).acetyltransferase inhibitor on COX-2 expression. A: Expression of
. B: The mean (±SEM) of IOD of COX-2/β-actin in all rats on mRNA
rats. Typical results are shown. D: The mean (±SEM) of IOD of
S-treated CCI rats; NC: LV-NC-treated CCI rats; shp300:
I rats. *P < 0.05 vs. sham-operated group; #P < 0.05 vs. NS and
Figure 7 Double immunofluorescence staining shows that p300 (red) co-localized with COX-2 (green) in the dorsal horn of the spinal
cord. Arrows indicate the representative cells expressing both p300 andCOX-2 (Scale bars = 60um).
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normally develop on the 3rd day and stabilize on the 7th
day after surgery [30]. In the present study, to ensure a
steady-state of the pain, we began our treatments from
the 7th day following CCI. In the LV-shp300 and C646
treated groups, behavioral testing revealed that both the
mechanical allodynia and thermal hyperexcitability grad-
ually recovered to the baseline level, and reached their
peaks on the 14th day, indicating that these two p300 in-
hibition interferences had exerted their effects. There-
fore, at the maximum time point of the functional
changes, our study was mainly focused on the potential
mechanism.
Functioning as an integrator for many signal transduc-
tion pathways through interaction with numerous crit-
ical transcription factors and other functional proteins,
p300 is found to be highly sensitive to promoters and
potential enhancers. The binding for p300 analyzed by
ChIP, followed by sequencing, is positively correlated
with gene expression and acetylation levels, suggesting
that p300 is involved in transcriptional initiation [31]. As
epigenetic processes such as histone acetylation and
RNA interference have profound effects on inflamma-
tory cytokine metabolism, steroid responsiveness, and
opioid sensitivity, these processes are likely essential in
the development of chronic pain [32,33]. DNA is
wrapped around histone proteins, composing the chro-
matin; chromatin remodeling occurs through chemical
modifications of histone proteins. These modifications
decide how tightly or loosely the chromatin is packaged,
thus controlling gene accessibility and expression [34].
p300, as a HAT, via acetylating the N-terminal tail
lysines of core histones correlates strongly with active
transcription of genes [35,36].
To identify the cellular and epigenetic functions rele-
vant to p300 activities, we looked into the possibility of a
molecular interaction between p300 and COX-2. COX-
2, an inducible enzyme, strongly expresses in the spinal
cord under proinflammatory stimulation. It is crucial inthe generation of neuropathic pain [37] and in the main-
tenance of pain states [11]. Inflammation and nerve de-
generation, seen as direct effects of nerve injury, are
critical in the development of neuropathic pain states
[9,38,39]. COX-2 regulates the synthesis of multiple
inflammatory mediators by producing prostaglandins
that are potent algetic factors in sensitizing neuronal
responses. The resultant prostaglandin production
augments neuronal excitability in the spinal cord
(central sensitization) and in somatosensory pathways
[40]. On the contrary, administering COX-2 inhibitor
or inhibiting COX-2 activity decreases neuropathy-
induced prostaglandin levels and reduces generated
pain hypersensitivity [41].
The effect of p300 on the expression of COX-2 gene
was monitored in the present study. The results revealed
that the COX-2 gene expression was regulated at the
chromosomal level, and the p300 recruitment to COX-2
promoter region determined the level of COX-2 gene
expression in the CCI rats. These results were consistent
with the previous studies indicating that p300 is essential
for the regulation of COX-2 promoter activity [42-45].
Moreover, with the aid of acetylating the lysine residues
in the DNA binding regions, p300 was found to regulate
the expression of other pain-associated genes, such as c-
Jun, in another report [46].
We also found that the binding of p300 to COX-2 was
enhanced in vehicle treated CCI rats and further aug-
mented by a p300 overexpression. The enhanced p300
binding to COX-2 was correlated with an up-regulation
of COX-2 promoter activities. This enhancement in
p300 activities was abrogated by p300shRNA. These
results indicated p300’s importance in regulating COX-2
transcription in the neuropathic pain model. Our results
also showed that the p300-mediated COX-2 transcrip-
tional activation was dependent on its own HAT. The
inhibition of the HAT by C646 resulted in an approxi-
mate reduction of 52.24% in COX-2 promoter activity.
p300 HAT contributes to the accessibility of COX-2
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Therefore, it is reasonable to conclude that the overex-
pression of p300 in CCI rats actually enhances the
downstream transcription of pain-associated gene (such
as COX-2), and the upregulation of p300 expression in
the spinal cord may be a critical process in neuropathic
pain induced by CCI. In summary, the importance of
epigenetic mechanism for the development of chronic
neuropathic pain is clearly evidenced by the changes of
p300 expression during the course of neuropathy after
CCI and through inhibition of p300 expression. This is
additionally highlighted by the effect of p300 on COX-2
expression in this study even though detailed informa-
tion on p300’s role in chronic neuropathic pain has yet
to be revealed.
C646 is capable of specifically inhibiting the HAT do-
main of p300. It can produce 86% inhibition of p300
in vitro specifically [24] and can work well in the central
nervous system in vivo [47]. p300 regulates the down-
stream DNA expression, not only via binding to tran-
scription factors, but also through its acetyltransferase
activity [48]. Inhibition of the histone acetyltransferase
renders nucleosomal DNA less accessible to the tran-
scriptional machinery, thereby usually favoring transcrip-
tional silencing [49]. The blockage of p300 by C646
may lead to the inhibition of histone acetylation on
the COX-2 promoter region. Inhibition of p300 with
shRNA or C646 can reverse neuropathic pain and
reduce COX-2 levels significantly; and their suppressive
effects were similar, which is in line with the report
by Santer et al. [50].
While our results show that the inhibition of histone
acetylation suppresses the activity of p300 and COX-2,
reducing hyperalgesia in this CCI model, there are a few
studies showing that histone deacetylase (HDAC) inhibi-
tors reduce pain hyperalgesia as a result of an increased
histone acetylation [51,52]. Most of these studies focus
on the relationship between HDAC and metabotropic
glutamate2 (mGlu2) receptor or gamma-aminobutyric
acid (GABA) synaptic function. Since individual HAT or
HDAC binds on the promoter of specific genes, it may
play different roles depending on the downstream target
gene is pro-hyperalgesia or anti-hyperalgesia. As for
p300 in the present study, it was found combined to the
promoter of COX-2, one of the well-described painful
genes. Moreover, even though GABAA receptors have an
important role in inflammatory pain mechanisms in
Complete Freund’s Adjuvant (CFA) model [51], spinal
GABAergic associated mechanism is found unnecessary
for the development of neuropathic pain in CCI model
[53]. These may explain the difference existed in the
findings of others studies and ours. As the main focus of
this study was to explore the potential effect of p300 and
its possible epigenetic role in neuropathic pain, twodifferent approaches were used to accomplish the goal;
to down-regulate p300 with specific shRNA, and to
chemically inhibit the acetyltransferase activity of p300
using C646. We did not determine the optimal dose to
reverse neuropathic pain in CCI rats, nor did we com-
pare the inhibiting efficiency with other p300 inhibitors
in an equivalent dose. In addition, behavioral changes
were used as the main markers for measuring the pain
and treatment effects; we did not examine other signs
related to antinociception or neuropathic pain. There-
fore, further studies will expand this observation of
neuropathic pain and p300 acetyltransferase activity into
other target molecules in neuropathic pain, multi-time
point and long-term model after CCI.
Conclusions
Our results suggest that p300 may play an important
role in neuropathic pain through the COX-2-associated
signaling pathway in rats following CCI. The inhibition
of p300 with shRNA and C646 can functionally reverse
the behavior of pain and down-regulate the expression
of COX-2 (a downstream gene of p300) after CCI, which
suggests that p300 is epigenetically involved in neuro-
pathic pain through its acetyltransferase activity. This
provides some insights for further studies on the role of
histone acetylation in neuropathic pain. Targeting p300




Male Sprague–Dawley rats (220–250 g) were purchased
from the animal experiment center of Xiangya School of
Medicine (Central South University, Changsha, Hunan,
China). The rats were allowed to acclimate for one week
after arrival. All the animals had free access to food and
water in a temperature-controlled lab where the ambient
temperature was maintained at 22 ± 0.5 with a light/dark
cycle of 12:12 h. All animal procedures were performed
in accordance with the National Institutes of Health
guide for the care and use of Laboratory animals (NIH
Publications No. 8023, revised 1978) and the Chinese
Council’s Guide for the Care and Use of Laboratory Ani-
mals (issued in 1988). To prevent wound infection after
a surgical procedure, the surgical area was dusted with
streptomycin before suturing the incision in all the ani-
mals. All the protocols were approved by the Animal
Care Committee of Central South University. All efforts
were made to minimize animal suffering, and to reduce
the numbers of animals used in this study.
Intrathecal catheter implantation
Intrathecal catheter implantation was carried out under
deep anesthesia with 10% chloral hydrate (300–350 mg/
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Ningbo, China) was implanted into the subarachnoid
space in all rats as previously reported [54]. After 3 days
of recovery, 2% lidocaine (10 μl) was administered intra-
thecally to judge whether the intrathecal catheter im-
plantation was successful or not. Only the animals that
demonstrated paralysis within 30 s and completely
recovered within 30 min were used for further study
[55]. The rats were housed in pairs in a 1500U rat cage
that had a custom made wire fence in the middle after
surgery with free access to food and water. The rats that
exhibited gross motor impairment following surgery
were euthanized.
Chronic constriction injury (CCI) model
After 5 days of recovery from the implantation, all the
rats showed good recovery and no signs of wound infec-
tion. The rats were randomly divided into the following
groups (n = 10 each): sham-operated group, NS-treated
group, LV-NC-treated group, C37-treated group, LV-
shp300-treated group, and C646-treated group. Under
deep anesthesia, CCI was introduced using the surgical
procedure as described [56-58]. In brief, after exposing
the left sciatic nerve from the surrounding tissue, four
snug ligatures (4–0 chromic gut) were placed around the
nerve. The interval among ligatures was about 1 mm. In
the sham operation, the nerve was exposed but not
ligated. To avoid variation, all the surgical procedures
were performed by the same member of our team. The
wounds healed gradually with no infection after the
surgery.
Construction and production of lentiviral vectors
In order to minimize off-target effects [59], a BLAST
homology search based on sense and antisense
sequences was systematically performed to ensure
that a single mRNA sequence was targeted. The se-
quence for the siRNA targeting the rat p300 gene
(GenBank ID:XM_576312), and for the non-
silencing siRNA were as follows: shp300 (468–487 bp
of p300 gene), CAGCCCAGTGAATCAACCT [60];
non-silencing siRNA, TTCTCCGAACGTGTCACGT
[61]. The oligonucleotides designed according to
the structure of the siRNA were p300 sense 50- Taa
CAGCCCAGTGAATCAACCTCTCGAGAGGTTGATTC
ACTGGGCTGttTTTTTTC-30 and antisense 50- TCGA
GAAAAAAaaCAGCCCAGTGAATCAACCTCTCGAGAG
GTTGATTCACTGGGCTGttA-30, negative control sense
50-TTTCTCCGAACGTGTCACGTTTCAAGAGAACGTG
ACACGTTCGGAGAATTTTTTC-30 and antisense 50-
TCGAGAAAAAATTCTCCGAACGTGTCACGTTCTCT
TGAAACGTGACACGTTCGGAGAAA-30. Then the oli-
gonucleotides containing both the siRNA and control
siRNA sequences were constructed into the plasmidpGCSIL-shp300-GFP and pGCSIL-shp300 NC-GFP. The
packaged plasmids were then cloned into the lentiviral
vector pGCSIL-GFP (Shanghai GeneChem Co. China),
and the recombinant lentiviral vectors were designated as
LV-shp300 and LV-NC. To generate the lentivirus, the re-
combinant vector and packaged plasmids were cotrans-
duced into 293 T cells using lipofectamine 2000
(Invitrogen, USA). Lentivirus, with the human U6 pro-
moter carrying shp300, was generated as previously
described [62]. The final titer of recombinant virus was
1 × 109 TU/ml.
Drugs and treatments
C646 (Sigma) and dimethyl sulfoxide (DMSO, Sigma)
were obtained commercially. C37 (inactive analog of
C646) was a gift from Dr. David Meyers (Johns Hopkins
University, USA). Drug testing was delayed until the 7th
day after the surgery to ensure establishment of neuro-
pathic pain prior to the initiation of drug delivery. All
the drugs and treatment reagents were administrated
through the lumbar intrathecal catheter. Sham-operated
rats and NS-treated rats received 0.9% saline 10ul, and
shRNA-treated rats received LV-NC or LV-shp300
(10 μl, diluted with nutrient medium) on day 7 after
CCI. C37-treated and C646-treated rats received C37
and C646 (10 ul, diluted with 10%DMSO, one dose per
day) from days 7 to 14 after CCI surgery. After the vec-
tors or drugs were administered, the catheter was
flushed with 5ul 0.9% saline.
Neuropathic pain measurements
Ipsilateral mechanical allodynia in all rats was tested
with 2390 Electronic von Frey Anesthesiometer (IITC
Life Science, USA) as previously reported [63]. Thermal
hyperalgesia was tested with Hargreaves Tes7370 (Ugo
Basile, Comerio, Italy). The measurements were repeated
three times with an interval of 5 minutes in each rat.
MWT and TWL of all rats were measured before CCI,
and on days 3, 5, 7, 10, 12 and 14 after CCI. All the be-
havioral tests were done by the same observer unaware
of animal treatments.
Sample preparation
On day 14 after CCI, the rats were killed and perfused
immediately with 400 ml-500 ml of cold normal saline
through the ascending aorta. Then their lumbar spinal
cords were quickly removed. The tissues for ChIP, RT-
PCR and western blot analysis were kept in −80°C. Tis-
sues used for histomorphological observations were
post-fixed with 4% paraformaldehyde for 8 h in 4°C.
Samples from LV-NC and LV-shp300-treated rats were
also made into frozen sections and observed under the
fluorescent microscope.
Zhu et al. Molecular Pain 2012, 8:84 Page 9 of 11
http://www.molecularpain.com/content/8/1/84Chromatin immunoprecipitation (ChIP) assay
The assays were performed using the Upstate Biotech-
nology ChIP assay kit. The spinal cord tissue was cut
into 1 mm slices and crossed-linked in 1.5% formalde-
hyde for 10 minutes. Then they were homogenized with
phosphate-buffered saline after glycine neutralizing. The
cell suspension was centrifuged at 12,000 g for 10 min-
utes, and SDS lysis buffer was added to the pellets. One
third of the lysate was used as DNA input control. Anti-
p300 antibody or non-immune rabbit IgG was used to
immunoprecipitate the DNA-p300 protein complex.
Immunocomplexes were collected by using protein
Aagarose beads in slurry (Upstate Biotechnology, USA)
after overnight antibody incubation. The precipitates
were washed extensively and incubated in the elution
buffer (1% SDS and 0.1 M NaHCO3) at 37°C for 20 min-
utes. Then the protein-DNA complexes were subjected
to reverse cross-linking, protease digestion, and purifica-
tion using a commercial kit (Qiagen, Germany).
The transcriptional start site of COX-2 is located at
the 713 bp from the 50 end of the COX-2 precursor se-
quence (http://www.ncbi.nlm.nih.gov/nuccore/NW_047397.1?
from=12399230&to=12406343&report=genbank). The rat
COX-2 DNA fragment −192/+127 was considered for the pu-
tative promoters because of containing key regulatory ele-
ments that correlates with many diseases [64,65]. In
addition, the TFSearch software revealed the −49/+127 re-
gion of the COX-2 precursor sequence to be highly
enriched in p300 binding sites. Therefore, the specific
COX-2 primer was set at segment from −50 to +150,
which contains the putative p300 binding site. Specific
COX-2 promoter primers were used to amplify the rat
COX-2 promoter region with following sequences:
50primer, ACCTCTGCGATGCTCTTCCG; and 30primer,
GCTCAGGCGCTTTGCCAATA. The real time PCR was
performed under standard cycling conditions (95°C for
5 min, followed by 40 cycles at 94°C for 20 s, 59°C for 20 s
and 72°C for 20 s). Each real time PCR reaction was done
in triplicate.
Reverse transcription PCR (RT-PCR) analysis
Total RNA was extracted from the lumber spinal cord
using Trizol Reagent (Invitrogen, USA). cDNA synthesis
was performed by reverse transcription. The primers
used were as follows: p300 primer sequences were for-
ward 50-GCTAATGGAGAAGTGAGGCAGT-30, reverse
50-TTTGAGAGGAAGACACACAGGA-30; COX-2 pri-
mer sequences were forward 50-TGGTGCCGGGTCTG
ATGATG-30, reverse 50-GCAATGCGGTTCTGATAC
TG-30. The program for p300 was 94°C for 30 s, 60°C for
30s, 72°C for 30 s and 30 cycles, and it was 94°C for
1 min, 54°C for 1 min, 72°C for 1 min and 30 cycles,
for COX-2. β-actin primer sequences were forward 50-
CACGATGGAGGGGCCGGACTCATC-30, reverse 50-TAAAGACCTCTATGCCAACACAGT-30. And the prog-
ram was 94°C for 30 s, 63°C for 30 s, 72°C for 30 s and
28 cycles. Each PCR sample was incubated for 5 min at
94°C before the initial denaturation and 7 min at 72°C
after the last PCR cycle. The products were analyzed by
agarose gel electrophoresis containing ethidium bromide.
Bands intensity was analyzed and semi-quantified using
Quantity One software (Bio-Rad, USA). Results were nor-
malized to β-actin levels.Western blot analysis
Proteins were extracted from the spinal cord using the
nucleoprotein and cytoplasmic protein extraction kit
(Keygen Biotech, China). Each protein sample (20 μg)
was separated on an 8% sodium dodecyl sulfate poly-
acrylamide gel and electrotransferred to a nitrocellulose
membrane in Trans-Blot electrophoresis Transfer Cell
(Bio-Rad, USA). The membranes were blocked with 5%
nonfat dry milk in phosphate-buffered saline with 0.05%
Tween 20 for 1 h. Primary antibody incubation (COX-2
dilution: 1:1000, Abcam, USA; p300 dilution: 1:300, Santa
Cruz, USA) was performed at room temperature on a
shaker for 1 h and then at 4°C overnight, followed by in-
cubation with peroxidase conjugated secondary antibody
(1:5000, Sigma, St Louis, MO, USA) for 1 h. Protein
brands were visualized by chemiluminescence using an
ECL kit (Pierce, USA). Densitometric analysis was carried
out using Quantity One software (Bio-Rad), and the
results were normalized to loading control.Immunocytochemistry analysis
The lumbar spinal cord tissues were post-fixed with 4%
paraformaldehyde for 8 h. After dehydration, the tissues
were embedded in paraffin and sectioned at a thickness
of 5 μm. The sections were dewaxed and treated with
0.01 M citrate buffer at 80°C for 20 min for antigen re-
trieval and then blocked with 3% goat serum for 1 h.
Afterwards, the sections were incubated for 24 h at 4°C
with rabbit polyclonal anti-COX-2 antibody (dilution at
1:300; Abcam, USA) or anti-p300 antibody (dilution at
1:300; Santa Cruz, USA), followed by incubation with
biotinylated anti-rabbit IgG (dilution at 1:2,000; vector).
After being processed with Elite Vectastain ABC
kit (Vector), the immunoprecipitates were developed
with diaminobenzidine (DAB, Vector). Negative controls
lacked the primary antibody. Images of immunocyto-
chemistry were digitally captured using a Nikon N-
STORM Professional CCD Camera. Cell counting was
performed by two observers unaware of animal treat-
ments. For colocalization, the red dihydroxyfluorane (di-
lution at 1:100; 16010045) and green dihydroxyfluorane
(dilution at 1:200; 16010084) were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA). Double-
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scanning microscope (TCS SP5, Mannheim, Germany).
Statistical analysis
Data were reported as mean ± SEM. CHIP measure-
ments, p300, and COX-2 expression among groups were
analyzed with the one-way analysis of variance
(ANOVA) followed by Student-Newman-Keuls post hoc
test. Behavioral data were assessed by two-way ANOVA
with repetitive measurements with group and time post-
CCI surgery as variables followed by Holm-Sidak post-
hoc analysis. The significance level was set at P < 0.05.
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